COSCIENS Biopharma (CSCI) 6-K 9 Aug 23 Current report (foreign) Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2023
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-38064
Entity Registrant Name	Aeterna Zentaris Inc.
Entity Central Index Key	0001113423
Entity Address, Address Line One	c/o Norton Rose Fulbright Canada, LLP
Entity Address, Address Line Two	222 Bay Street
Entity Address, Address Line Three	Suite 3000, PO Box 53,
Entity Address, City or Town	Toronto ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	M5K 1E7

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 42,186	$ 50,611
Trade and other receivables	185	732
Inventory	93	229
Income taxes receivable	792	1,428
Prepaid expenses and other current assets	2,637	2,488
Total current assets	45,893	55,488
Non-current assets
Restricted cash equivalents	325	322
Property and equipment	265	216
Total non-current assets	591	538
Total assets	46,483	56,026
Current liabilities
Payables and accrued liabilities	3,572	3,828
Provisions	49	45
Income taxes payable	109	108
Deferred revenues (note 3)	202	2,949
Lease liabilities	145	114
Total current liabilities	4,077	7,044
Non-current liabilities
Deferred revenues (note 3)	1,580	1,684
Deferred gain	111	110
Lease liabilities	85	65
Employee future benefits (note 4)	11,381	11,159
Provisions	170	188
Total non-current liabilities	13,327	13,206
Total liabilities	17,404	20,250
Shareholders’ equity
Share capital (note 5)	293,410	293,410
Warrants	5,085	5,085
Contributed surplus	90,654	90,332
Deficit	(358,936)	(352,084)
Accumulated other comprehensive loss	(1,134)	(967)
Total Shareholders’ equity	29,079	35,776
Total liabilities and shareholders’ equity	$ 46,483	$ 56,026

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Issued capital [member]	Warrants [member]	Other equity interest [member]	Retained earnings [member]	Accumulated other comprehensive income [member]	Total
Balance – Value at Dec. 31, 2021	$ 293,410	$ 5,085	$ 89,788	$ (334,619)	$ (678)	$ 52,986
IfrsStatementLineItems [Line Items]
Net loss				(6,856)		(6,856)
Foreign currency translation adjustments					79	79
Actuarial gain on defined benefit plans				8,025		8,025
Comprehensive income (loss)				1,169	79	1,248
Share-based compensation costs			60			60
Balance – Value at Jun. 30, 2022	293,410	5,085	89,848	(333,450)	(599)	54,294
Balance – Value at Dec. 31, 2022	293,410	5,085	90,332	(352,084)	(967)	35,776
IfrsStatementLineItems [Line Items]
Net loss				(6,772)		(6,772)
Foreign currency translation adjustments					(167)	(167)
Actuarial gain on defined benefit plans				(80)		(80)
Comprehensive income (loss)				(6,852)	(167)	(7,019)
Share-based compensation costs			322			322
Balance – Value at Jun. 30, 2023	$ 293,410	$ 5,085	$ 90,654	$ (358,936)	$ (1,134)	$ 29,079

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Profit or loss [abstract]
Revenues (note 3)	$ 2,246	$ (222)	$ 4,374	$ 1,295
Expenses
Cost of sales	139	13	156	92
Research and development	2,929	2,398	6,941	4,788
Selling, general and administrative	2,033	2,083	4,339	3,944
Total expenses	5,101	4,494	11,436	8,824
Loss from operations	(2,855)	(4,716)	(7,062)	(7,529)
Gain (loss) due to changes in foreign currency exchange rates	27	502	(32)	676
Interest income	307		320
Other finance income (costs)	3	(2)	2	(3)
Net finance income	337	500	290	673
Loss before income taxes	(2,518)	(4,216)	(6,772)	(6,856)
Income tax recovery
Net loss	(2,518)	(4,216)	(6,772)	(6,856)
Items that may be reclassified subsequently to profit or loss:
Foreign currency translation adjustments	3	42	(167)	79
Items that will not be reclassified to profit or loss:
Actuarial gain on defined benefit plans (note 4)	83	5,276	(80)	8,025
Comprehensive (loss) income	$ (2,432)	$ 1,102	$ (7,019)	$ 1,248
Basic loss per share (note 7)	$ (0.52)	$ (0.87)	$ (1.39)	$ (1.41)
Diluted loss per share (note 7)	$ (0.52)	$ (0.87)	$ (1.39)	$ (1.41)
Weighted average number of shares outstanding, basic	4,855,876	4,855,876	4,855,876	4,855,876
Weighted average number of shares outstanding, diluted	4,855,876	4,855,876	4,855,876	4,855,876

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss for the period	$ (2,518)	$ (4,216)	$ (6,772)	$ (6,856)
Items not affecting cash and cash equivalents:
Provisions	18	7	10	5
Depreciation and amortization	44	35	84	71
Share-based compensation costs	306	33	323	60
Employee future benefits	130	98	265	197
Amortization of deferred revenues	(794)	124	(1,554)	(704)
Net foreign exchange differences	(9)	(513)	(1)	(687)
Other non-cash items	5	495	5	509
Refund (payment) of income taxes	647	(51)	647	830
Changes in operating assets and liabilities (note 6)	(2,122)	(862)	(1,361)	264
Net cash used in operating activities	(4,293)	(4,850)	(8,354)	(6,311)
Cash flows from financing activities
Payments on lease liabilities	(42)	(34)	(80)	(68)
Net cash used in financing activities	(42)	(34)	(80)	(68)
Cash flows from investing activities
Purchase of property and equipment	(3)	(42)	(5)	(48)
Net cash used in investing activities	(3)	(42)	(5)	(48)
Effect of exchange rate changes on cash and cash equivalents	(36)	(513)	14	(716)
Net change in cash and cash equivalents	(4,374)	(5,439)	(8,425)	(7,143)
Cash and cash equivalents – Beginning of period	46,560	63,596	50,611	65,300
Cash and cash equivalents – End of period	$ 42,186	$ 58,157	$ 42,186	$ 58,157

Business overview

Business overview	6 Months Ended
	Jun. 30, 2023
Business Overview
Business overview	1. Business overview Summary of business Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen ® The Company is also dedicated to the development of therapeutic assets and has taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across several indications with a focus on rare or orphan indications. These unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the “Board”) on August 8, 2023.

Basis of presentation

Basis of presentation	6 Months Ended
	Jun. 30, 2023
Basis Of Presentation
Basis of presentation	2. Basis of presentation These unaudited condensed interim consolidated financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting The unaudited condensed interim consolidated financial statements do not include all the notes normally included in annual consolidated financial statements. Accordingly, these unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022. The accounting policies used in these condensed interim consolidated financial statements are consistent with those presented in the Company’s annual consolidated financial statements. New standards and amendments Effective January 1, 2023, the Company adopted the Disclosure of Accounting Policies (amendments to IAS 1 and IFRS Practice Statement 2). The amendments to IAS 1 require that the Company discloses its material accounting policies instead of its significant accounting policies. As a result of the adoption of these amendments, there were no adjustments to the presentation or amounts recognized in the interim financial statements. Critical accounting estimates and judgements The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgements, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared. Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgements in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgements used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue [abstract]
Revenue	3. Revenue The Company derives revenue from the transfer of goods and services over time and at a point in time in the following categories: Summary of revenue from transfer of goods and services 2023 2022 2023 2022 Three months ended Six months ended June 30, June 30, 2023 2022 2023 2022 $ $ $ $ License fees 795 (206 ) 1,554 226 Development services 1,402 (77 ) 2,741 889 Product sales - - - 57 Royalties 7 24 26 43 Supply chain 42 37 53 80 Total 2,246 (222 ) 4,374 1,295 The Company recorded revenue for the transfer of services over time for the three-months ended June 30, 2023, of $ 2,197 283 4,295 1,115 49 61 79 180 Pharmanovia: On March 15, 2023, with the Company’s consent, Consilient Health (“CH”) entered into an assignment agreement with Pharmanovia to transfer the current licensing agreement for the commercialization of macimorelin in the European Economic Area and the United Kingdom to Pharmanovia, as well as the current supply agreement pursuant to which the Company agreed to provide the licensed product (together, the “Assignment Agreement”). Also on March 15, 2023, the Company and Pharmanovia entered into an amendment agreement, pursuant to which the Company provided its acknowledgement and consent to the Assignment Agreement and agreed to certain amended terms which do not materially differ from the previous license and supply agreement with CH. Subsequent to the execution of the Assignment Agreement, the aggregate amount of the transaction price allocated to the Company’s unsatisfied performance obligations was $ 1,658 1,540 1,233 1,145 425 395 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) Novo Nordisk Health Care AG: On August 26, 2022, Novo provided the Company with a notice of termination of the Novo Amendment. Under the terms of the Novo Amendment, the termination was effective May 23, 2023, upon the completion of a 270-day notice period (“notice period”). Upon termination, the rights and licenses granted by the Company to Novo under the Novo Amendment returned to the Company, and the Company regained full rights to continue the clinical development and future commercialization of Macrilen™. Following the notice of termination and throughout the 270-day notice period, as per the terms of the Novo Amendment, Novo continued to fund DETECT-trial costs up to $ 10.1 9.4 Liabilities related to contracts with customers The following table provides a summary of deferred revenue balances: Summary of deferred revenue June 30, 2023 Current Non-current Total $ $ $ Novo Nordisk Health Care - - - Pharmanovia 193 1,459 1,652 NK Meditech 9 121 130 202 1,580 1,782 December 31, 2022 Current Non-current Total $ $ $ Novo Nordisk Health Care 2,914 - 2,914 Consilient Health 35 1,556 1,591 NK Meditech - 128 128 2,949 1,684 4,633 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Employee future benefits

Employee future benefits	6 Months Ended
	Jun. 30, 2023
Employee Future Benefits
Employee future benefits	4. Employee future benefits The change in the Company’s employee future benefit obligations is summarized as follows: Summary of net defined benefit liability asset benefit plans benefit plans Total Total Six months ended June 30, 2023 Year ended Pension Other benefit plans benefit plans Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the period 21,657 93 21,750 29,412 Current service cost 63 6 69 142 Interest cost 400 2 402 295 Actuarial loss (gain) from changes in financial assumptions 143 - 143 (5,915 ) Benefits paid (380 ) - (380 ) (752 ) Impact of foreign exchange rate changes 261 1 262 (1,432 ) Balances – End of the period 22,144 102 22,246 21,750 Change in plan assets Balances – Beginning of the period 10,591 - 10,591 11,927 Interest income from plan assets 198 - 198 120 Employer contributions 14 - 14 45 Employee contributions 8 - 8 10 Benefits paid (136 ) - (136 ) (247 ) Remeasurement of plan assets 63 - 63 (641 ) Impact of foreign exchange rate changes 127 - 127 (623 ) Balances – End of the period 10,865 - 10,865 10,591 Net liability of the unfunded plans 10,867 102 10,969 10,787 Net liability of the funded plans 412 - 412 372 Net amount recognized as Employee future benefits 11,279 102 11,381 11,159 Amounts recognized: In net loss 257 8 265 295 Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income (80 ) - (80 ) 5,262 The calculation of the employee future benefit obligation is sensitive to the discount rate assumption and other assumptions such as the rate of the pension benefit increase. Discount rates were 3.70 3.75 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Shareholders_ equity

Shareholders’ equity	6 Months Ended
	Jun. 30, 2023
Shareholders Equity
Shareholders’ equity	5. Shareholders’ equity Share capital The Company has authorized an unlimited number of common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value. Summary of share capital Common shares Amount # $ Balance – December 31, 2022 4,855,876 293,410 - - Balance – June 30, 2023 4,855,876 293,410 On July 15, 2022, the Company’s shareholders and board of directors approved an amendment to the Company’s articles of incorporation to effect a 1-for-25 1-for-25 Accordingly, all common shares, DSU, warrants, stock options and per share amounts in these interim condensed consolidated financial statements have been retroactively adjusted for all periods presented to give effect to the share consolidation (reverse split). Share-based compensation On January 17, 2023, the Company granted 14,000 2,000 Summary of assumptions to determine share-based compensation costs over the life of awards June 30, June 30, Expected dividend yield $ 0.00 $ 0.00 Expected volatility 104.46 % 115.75 % Risk-free annual interest rate 3.56 % 1.59 % Expected life (years) 5.45 5.72 Share price $ 3.75 $ 8.88 Exercise price $ 3.75 $ 8.88 Grant date fair value $ 2.99 $ 7.47 The expected volatility of these stock options was determined using historical volatility rates and the expected life was determined using the weighted average life of past options issued. Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) The compensation expense for the three months ended June 30, 2023, was $ 22 33 39 60 Summary of number and weighted average exercise prices of share options Stock options Weighted average exercise price # $ Balance – January 1, 2023 42,030 20.05 Granted 14,000 3.75 Cancelled / Forfeited - - Balance – June 30, 2023 56,030 15.98 Stock options Weighted average exercise price # $ Balance – January 1, 2022 43,455 22.00 Granted 2,000 8.88 Cancelled / Forfeited (2,399 ) 10.98 Balance – June 30, 2022 43,056 21.95 Deferred share units On June 14, 2023, the Company granted 100,000 nil 284 nil Summary of DSU activity 2023 2022 # # Balance – January 1, 96,920 16,920 Granted 100,000 - Balance – June 30, 196,920 16,920 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Supplemental disclosure of cash

Supplemental disclosure of cash flow information	6 Months Ended
	Jun. 30, 2023
Supplemental Disclosure Of Cash Flow Information
Supplemental disclosure of cash flow information	6. Supplemental disclosure of cash flow information Disclosure of changes in operating assets and liabilities 2023 2022 2023 2022 Three months ended Six months ended June 30, June 30, 2023 2022 2023 2022 $ $ $ $ Changes in operating assets and liabilities: Trade and other receivables 199 (255 ) 402 220 Inventory 135 - 140 (206 ) Prepaid expenses and other current assets (748 ) (1,471 ) (122 ) (759 ) Payables and accrued liabilities (398 ) (40 ) (163 ) 119 Deferred revenues (1,205 ) 1,001 (1,359 ) 1,008 Provision for restructuring and other costs 4 - (5 ) - Employee future benefits (109 ) (97 ) (254 ) (118 ) Increase (decrease) in operating assets and liabilities (2,122 ) (862 ) (1,361 ) 264

Net loss per share

Net loss per share	6 Months Ended
	Jun. 30, 2023
Net Loss Per Share
Net loss per share	7. Net loss per share The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of pertinent data relating to computation of basic and diluted net loss per share 2023 2022 2023 2022 Three months ended Six months ended June 30, June 30, 2023 2022 2023 2022 $ $ $ $ Net loss (2,518 ) (4,216 ) (6,772 ) (6,856 ) Basic and diluted weighted-average shares outstanding 4,855,876 4,855,876 4,855,876 4,855,876 Basic weighted-average shares outstanding 4,855,876 4,855,876 4,855,876 4,855,876 Basic and diluted loss per share (0.52 ) (0.87 ) (1.39 ) (1.41 ) Basic loss per share (0.52 ) (0.87 ) (1.39 ) (1.41 ) Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: Stock options and DSUs 252,950 62,375 252,950 62,375 Warrants 457,648 457,648 457,648 457,648 Anti-dilutive shares

Segment information

Segment information	6 Months Ended
	Jun. 30, 2023
Segment Information
Segment information	8. Segment information The Company operates in a single operating segment, being the biopharmaceutical segment. Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Commitments

Commitments	6 Months Ended
	Jun. 30, 2023
Commitments
Commitments	9. Commitments Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows: Schedule of expected future minimum lease payments TOTAL $ Less than 1 year 7,586 1 - 3 years 151 4 - 5 years 37 More than 5 years - Total 7,774 In 2021, the Company executed various agreements including in-licensing and similar arrangements with development partners. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. The Company may have to pay up to $ 38,887

Basis of presentation (Policies

Basis of presentation (Policies)	6 Months Ended
	Jun. 30, 2023
Basis Of Presentation
New standards and amendments	New standards and amendments Effective January 1, 2023, the Company adopted the Disclosure of Accounting Policies (amendments to IAS 1 and IFRS Practice Statement 2). The amendments to IAS 1 require that the Company discloses its material accounting policies instead of its significant accounting policies. As a result of the adoption of these amendments, there were no adjustments to the presentation or amounts recognized in the interim financial statements.
Critical accounting estimates and judgements	Critical accounting estimates and judgements The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgements, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared. Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgements in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgements used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue [abstract]
Summary of revenue from transfer of goods and services	The Company derives revenue from the transfer of goods and services over time and at a point in time in the following categories: Summary of revenue from transfer of goods and services 2023 2022 2023 2022 Three months ended Six months ended June 30, June 30, 2023 2022 2023 2022 $ $ $ $ License fees 795 (206 ) 1,554 226 Development services 1,402 (77 ) 2,741 889 Product sales - - - 57 Royalties 7 24 26 43 Supply chain 42 37 53 80 Total 2,246 (222 ) 4,374 1,295
Summary of deferred revenue	The following table provides a summary of deferred revenue balances: Summary of deferred revenue June 30, 2023 Current Non-current Total $ $ $ Novo Nordisk Health Care - - - Pharmanovia 193 1,459 1,652 NK Meditech 9 121 130 202 1,580 1,782 December 31, 2022 Current Non-current Total $ $ $ Novo Nordisk Health Care 2,914 - 2,914 Consilient Health 35 1,556 1,591 NK Meditech - 128 128 2,949 1,684 4,633

Employee future benefits (Table

Employee future benefits (Tables)	6 Months Ended
	Jun. 30, 2023
Employee Future Benefits
Summary of net defined benefit liability asset	The change in the Company’s employee future benefit obligations is summarized as follows: Summary of net defined benefit liability asset benefit plans benefit plans Total Total Six months ended June 30, 2023 Year ended Pension Other benefit plans benefit plans Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the period 21,657 93 21,750 29,412 Current service cost 63 6 69 142 Interest cost 400 2 402 295 Actuarial loss (gain) from changes in financial assumptions 143 - 143 (5,915 ) Benefits paid (380 ) - (380 ) (752 ) Impact of foreign exchange rate changes 261 1 262 (1,432 ) Balances – End of the period 22,144 102 22,246 21,750 Change in plan assets Balances – Beginning of the period 10,591 - 10,591 11,927 Interest income from plan assets 198 - 198 120 Employer contributions 14 - 14 45 Employee contributions 8 - 8 10 Benefits paid (136 ) - (136 ) (247 ) Remeasurement of plan assets 63 - 63 (641 ) Impact of foreign exchange rate changes 127 - 127 (623 ) Balances – End of the period 10,865 - 10,865 10,591 Net liability of the unfunded plans 10,867 102 10,969 10,787 Net liability of the funded plans 412 - 412 372 Net amount recognized as Employee future benefits 11,279 102 11,381 11,159 Amounts recognized: In net loss 257 8 265 295 Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income (80 ) - (80 ) 5,262

Shareholders_ equity (Tables)

Shareholders’ equity (Tables)	6 Months Ended
	Jun. 30, 2023
Shareholders Equity
Summary of share capital	Summary of share capital Common shares Amount # $ Balance – December 31, 2022 4,855,876 293,410 - - Balance – June 30, 2023 4,855,876 293,410
Summary of assumptions to determine share-based compensation costs over the life of awards	Summary of assumptions to determine share-based compensation costs over the life of awards June 30, June 30, Expected dividend yield $ 0.00 $ 0.00 Expected volatility 104.46 % 115.75 % Risk-free annual interest rate 3.56 % 1.59 % Expected life (years) 5.45 5.72 Share price $ 3.75 $ 8.88 Exercise price $ 3.75 $ 8.88 Grant date fair value $ 2.99 $ 7.47
Summary of number and weighted average exercise prices of share options	Summary of number and weighted average exercise prices of share options Stock options Weighted average exercise price # $ Balance – January 1, 2023 42,030 20.05 Granted 14,000 3.75 Cancelled / Forfeited - - Balance – June 30, 2023 56,030 15.98 Stock options Weighted average exercise price # $ Balance – January 1, 2022 43,455 22.00 Granted 2,000 8.88 Cancelled / Forfeited (2,399 ) 10.98 Balance – June 30, 2022 43,056 21.95
Summary of DSU activity	Summary of DSU activity 2023 2022 # # Balance – January 1, 96,920 16,920 Granted 100,000 - Balance – June 30, 196,920 16,920

Supplemental disclosure of ca_2

Supplemental disclosure of cash flow information (Tables)	6 Months Ended
	Jun. 30, 2023
Supplemental Disclosure Of Cash Flow Information
Disclosure of changes in operating assets and liabilities	Disclosure of changes in operating assets and liabilities 2023 2022 2023 2022 Three months ended Six months ended June 30, June 30, 2023 2022 2023 2022 $ $ $ $ Changes in operating assets and liabilities: Trade and other receivables 199 (255 ) 402 220 Inventory 135 - 140 (206 ) Prepaid expenses and other current assets (748 ) (1,471 ) (122 ) (759 ) Payables and accrued liabilities (398 ) (40 ) (163 ) 119 Deferred revenues (1,205 ) 1,001 (1,359 ) 1,008 Provision for restructuring and other costs 4 - (5 ) - Employee future benefits (109 ) (97 ) (254 ) (118 ) Increase (decrease) in operating assets and liabilities (2,122 ) (862 ) (1,361 ) 264

Net loss per share (Tables)

Net loss per share (Tables)	6 Months Ended
	Jun. 30, 2023
Net Loss Per Share
Summary of pertinent data relating to computation of basic and diluted net loss per share	The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of pertinent data relating to computation of basic and diluted net loss per share 2023 2022 2023 2022 Three months ended Six months ended June 30, June 30, 2023 2022 2023 2022 $ $ $ $ Net loss (2,518 ) (4,216 ) (6,772 ) (6,856 ) Basic and diluted weighted-average shares outstanding 4,855,876 4,855,876 4,855,876 4,855,876 Basic weighted-average shares outstanding 4,855,876 4,855,876 4,855,876 4,855,876 Basic and diluted loss per share (0.52 ) (0.87 ) (1.39 ) (1.41 ) Basic loss per share (0.52 ) (0.87 ) (1.39 ) (1.41 ) Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: Stock options and DSUs 252,950 62,375 252,950 62,375 Warrants 457,648 457,648 457,648 457,648 Anti-dilutive shares

Commitments (Tables)

Commitments (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments
Schedule of expected future minimum lease payments	Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows: Schedule of expected future minimum lease payments TOTAL $ Less than 1 year 7,586 1 - 3 years 151 4 - 5 years 37 More than 5 years - Total 7,774

Summary of revenue from transfe

Summary of revenue from transfer of goods and services (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
IfrsStatementLineItems [Line Items]
Total	$ 2,246	$ (222)	$ 4,374	$ 1,295
License Fees [Member]
IfrsStatementLineItems [Line Items]
Total	795	(206)	1,554	226
Development Services [Member]
IfrsStatementLineItems [Line Items]
Total	1,402	(77)	2,741	889
Product Sales [Member]
IfrsStatementLineItems [Line Items]
Total				57
Royalties [Member]
IfrsStatementLineItems [Line Items]
Total	7	24	26	43
Supply Chain [Member]
IfrsStatementLineItems [Line Items]
Total	$ 42	$ 37	$ 53	$ 80

Summary of deferred revenue (De

Summary of deferred revenue (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	$ 202	$ 2,949
Total Deferred Revenues Non Current	1,580	1,684
Total Deferred Revenues	1,782	4,633
Novo Nordisk Health Care [member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues		2,914
Total Deferred Revenues Non Current
Total Deferred Revenues		2,914
Pharmanovia [member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	193
Total Deferred Revenues Non Current	1,459
Total Deferred Revenues	1,652
NK Meditech [member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	9
Total Deferred Revenues Non Current	121	128
Total Deferred Revenues	$ 130	128
Consilient Health [member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues		35
Total Deferred Revenues Non Current		1,556
Total Deferred Revenues		$ 1,591

Revenue (Details Narrative)

Revenue (Details Narrative) € in Thousands, $ in Thousands			3 Months Ended		6 Months Ended
	May 23, 2023 USD ($)	May 23, 2023 EUR (€)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Mar. 15, 2023 USD ($)	Mar. 15, 2023 EUR (€)
IfrsStatementLineItems [Line Items]
Revenue			$ 2,246	$ (222)	$ 4,374	$ 1,295
Novo Nordisk Health Care AG [member]
IfrsStatementLineItems [Line Items]
Detect trial costs	$ 10,100	€ 9,400
Unsatisfied performance obligations [member]
IfrsStatementLineItems [Line Items]
Performance obligations							$ 1,658	€ 1,540
Indication performance obligation [member]
IfrsStatementLineItems [Line Items]
Performance obligations							1,233	1,145
Pediatric indication performance [member]
IfrsStatementLineItems [Line Items]
Performance obligations							$ 425	€ 395
Goods or services transferred over time [member]
IfrsStatementLineItems [Line Items]
Revenue			2,197	283	4,295	1,115
Goods or services transferred at point in time [member]
IfrsStatementLineItems [Line Items]
Revenue			$ 49	$ 61	$ 79	$ 180

Summary of net defined benefit

Summary of net defined benefit liability asset (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Change in plan liabilities
Balances – Beginning of the period	$ 21,750	$ 29,412
Current service cost	69	142
Interest cost	402	295
Actuarial loss (gain) from changes in financial assumptions	(143)	5,915
Benefits paid	(380)	(752)
Impact of foreign exchange rate changes	262	(1,432)
Balances – End of the period	22,246	21,750
Change in plan assets
Balances – Beginning of the period	10,591	11,927
Interest income from plan assets	198	120
Employer contributions	14	45
Employee contributions	8	10
Benefits paid	(136)	(247)
Remeasurement of plan assets	63	(641)
Impact of foreign exchange rate changes	127	(623)
Balances – End of the period	10,865	10,591
Net liability of the unfunded plans	10,969	10,787
Net liability of the funded plans	412	372
Net amount recognized as Employee future benefits	11,381	11,159
Amounts recognized:
In net loss	265	295
Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income	(80)	5,262
Pension defined benefit plans [member]
Change in plan liabilities
Balances – Beginning of the period	21,657
Current service cost	63
Interest cost	400
Actuarial loss (gain) from changes in financial assumptions	(143)
Benefits paid	(380)
Impact of foreign exchange rate changes	261
Balances – End of the period	22,144	21,657
Change in plan assets
Balances – Beginning of the period	10,591
Interest income from plan assets	198
Employer contributions	14
Employee contributions	8
Benefits paid	(136)
Remeasurement of plan assets	63
Impact of foreign exchange rate changes	127
Balances – End of the period	10,865	10,591
Net liability of the unfunded plans	10,867
Net liability of the funded plans	412
Net amount recognized as Employee future benefits	11,279
Amounts recognized:
In net loss	257
Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income	(80)
Other benefit plans [member]
Change in plan liabilities
Balances – Beginning of the period	93
Current service cost	6
Interest cost	2
Actuarial loss (gain) from changes in financial assumptions
Benefits paid
Impact of foreign exchange rate changes	1
Balances – End of the period	102	93
Change in plan assets
Balances – Beginning of the period
Interest income from plan assets
Employer contributions
Employee contributions
Benefits paid
Remeasurement of plan assets
Impact of foreign exchange rate changes
Balances – End of the period
Net liability of the unfunded plans	102
Net liability of the funded plans
Net amount recognized as Employee future benefits	102
Amounts recognized:
In net loss	8
Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income

Employee future benefits (Detai

Employee future benefits (Details Narrative)	Jun. 30, 2023	Dec. 31, 2022
Employee Future Benefits
Employee future benefit obligation	3.70%	3.75%

Summary of share capital (Detai

Summary of share capital (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
IfrsStatementLineItems [Line Items]
Balance – Value	$ 35,776	$ 54,294	$ 52,986
Balance – Value	$ 29,079	35,776	54,294
Issued capital [member]
IfrsStatementLineItems [Line Items]
Number of shares issued	4,855,876
Balance – Value	$ 293,410	$ 293,410	293,410
Number of shares issued	4,855,876	4,855,876
Balance – Value	$ 293,410	$ 293,410	$ 293,410

Summary of assumptions to deter

Summary of assumptions to determine share-based compensation costs over the life of awards (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Shareholders Equity
Expected dividend yield	0%	0%
Expected volatility	104.46%	115.75%
Risk-free annual interest rate	3.56%	1.59%
Expected life (years)	5 years 5 months 12 days	5 years 8 months 19 days
Share price	$ 3.75	$ 8.88
Exercise price	3.75	8.88
Grant date fair value	$ 2.99	$ 7.47

Summary of number and weighted

Summary of number and weighted average exercise prices of share options (Details)	6 Months Ended
	Jun. 30, 2023 shares $ / shares	Jun. 30, 2022 shares $ / shares
Shareholders Equity
Number of Options, Beginning | shares	42,030	43,455
Weighted average exercise price, beginning | $ / shares	$ 20.05	$ 22
Number of Options, Granted | shares	14,000	2,000
Weighted average exercise price, granted | $ / shares	$ 3.75	$ 8.88
Number of Options, Canceled/Forfeited | shares		(2,399)
Weighted average exercise price, cancelled/forfeited | $ / shares		$ 10.98
Number of Options, Ending | shares	56,030	43,056
Weighted average exercise price, ending | $ / shares	$ 15.98	$ 21.95

Summary of DSU activity (Detail

Summary of DSU activity (Details) - Deferred Share Unit [member] - shares			6 Months Ended
	Jun. 14, 2023	Jun. 14, 2022	Jun. 30, 2023	Jun. 30, 2022
IfrsStatementLineItems [Line Items]
Balance – January 1,			96,920	16,920
Granted	100,000		100,000
Balance – June 30,			196,920	16,920

Shareholders_ equity (Details N

Shareholders’ equity (Details Narrative) $ in Thousands						3 Months Ended		6 Months Ended
	Jun. 14, 2023 shares	Jan. 17, 2023 shares	Jul. 15, 2022	Jun. 14, 2022 shares	Jan. 17, 2022 shares	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) shares	Jun. 30, 2022 USD ($) shares
IfrsStatementLineItems [Line Items]
Number of options, granted								14,000	2,000
Compensation expenses | $						$ 22	$ 33	$ 39	$ 60
Deferred Share Unit [member]
IfrsStatementLineItems [Line Items]
Compensation expenses | $						$ 284		$ 284
Number of share units granted	100,000							100,000
2018 Long Term Incentive Plan [member]
IfrsStatementLineItems [Line Items]
Number of options, granted		14,000			2,000
Shareholders and Board of Directors [member]
IfrsStatementLineItems [Line Items]
Reverse stock split			1-for-25
Deferred Stock Units [member]
IfrsStatementLineItems [Line Items]
Reverse stock split			1-for-25

Disclosure of changes in operat

Disclosure of changes in operating assets and liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Supplemental Disclosure Of Cash Flow Information
Trade and other receivables	$ 199	$ (255)	$ 402	$ 220
Inventory	135		140	(206)
Prepaid expenses and other current assets	(748)	(1,471)	(122)	(759)
Payables and accrued liabilities	(398)	(40)	(163)	119
Deferred revenues	(1,205)	1,001	(1,359)	1,008
Provision for restructuring and other costs	4		(5)
Employee future benefits	(109)	(97)	(254)	(118)
Increase (decrease) in operating assets and liabilities	$ (2,122)	$ (862)	$ (1,361)	$ 264

Summary of pertinent data relat

Summary of pertinent data relating to computation of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
IfrsStatementLineItems [Line Items]
Net loss	$ (2,518)	$ (4,216)	$ (6,772)	$ (6,856)
Basic weighted-average shares outstanding	4,855,876	4,855,876	4,855,876	4,855,876
Diluted weighted-average shares outstanding	4,855,876	4,855,876	4,855,876	4,855,876
Basic loss per share	$ (0.52)	$ (0.87)	$ (1.39)	$ (1.41)
Diluted loss per share	$ (0.52)	$ (0.87)	$ (1.39)	$ (1.41)
Employee Stock Option 1 Deferred Stock Units [member]
Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
Anti-dilutive shares	252,950	62,375	252,950	62,375
Warrants [member]
Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
Anti-dilutive shares	457,648	457,648	457,648	457,648

Schedule of expected future min

Schedule of expected future minimum lease payments (Details) $ in Thousands	Jun. 30, 2023 USD ($)
IfrsStatementLineItems [Line Items]
Total	$ 7,774
Not later than one year [member]
IfrsStatementLineItems [Line Items]
Total	7,586
1 to 3 Years [member]
IfrsStatementLineItems [Line Items]
Total	151
4 to 5 Years [member]
IfrsStatementLineItems [Line Items]
Total	37
Later than five years [member]
IfrsStatementLineItems [Line Items]
Total

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Minimum lease payments net	$ 7,774
Top of range [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments net		$ 38,887